News tagged with clopidogrel
Researchers study under-recognised and under-treated prothrombotic condition: High platelet reactivity despite treatment
Within the past decade, the variability in pharmacodynamic response and moderate antiplatelet efficacy of clopidogrel has raised major concerns, in particular because it is associated with an increased risk for ischemic events ...
Cardiology May 06, 2013 | not rated yet | 0
(HealthDay News) —Prescription drug prices at U.S. pharmacies can vary widely, and failing to shop around could result in people overpaying by as much as $100 or more a month on average, depending on the ...
Medications Mar 28, 2013 | not rated yet | 0
Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots.
Cardiology Mar 13, 2013 | not rated yet | 0 |
(HealthDay)—In the search for better medicines to safely help heart patients, clinical trials testing three new drugs appear to offer some promise.
Cardiology Mar 11, 2013 | 4 / 5 (1) | 0
The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX ...
Cardiology Mar 11, 2013 | not rated yet | 1
A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent ...
Cardiology Mar 11, 2013 | not rated yet | 0
(Medical Xpress)—An experimental drug has been shown to be significantly more effective at preventing blood clots during coronary stenting procedures compared to the anti-clotting agent now typically used, according to ...
Cardiology Mar 11, 2013 | not rated yet | 0 |
Major risks of dual and triple antithrombotic therapy in patients with newly diagnosed atrial fibrillation
According to Dr. Samy Suissa, Director of Clinical Epidemiology, Jewish General Hospital, and Professor of Epidemiology, McGill University in Montreal, Canada, "treating physicians need to consider the clinical effectiveness ...
Cardiology Mar 05, 2013 | not rated yet | 0
(HealthDay)—Prehospital use of antiplatelet therapy, either aspirin/clopidogrel or dual antiplatelet therapy (DAPT), is associated with a lower incidence of major adverse cardiac events after saphenous ...
Cardiology Jan 28, 2013 | not rated yet | 0
Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel ...
Cardiology Dec 18, 2012 | not rated yet | 0 |
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to ...
Cardiology Nov 06, 2012 | 5 / 5 (1) | 0
The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke ...
Cardiology Nov 05, 2012 | not rated yet | 0 |
Low responsiveness to clopidogrel predicts stent thrombosis, heart attack: But is not directly linked to death
Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible heart attack; conversely, patients with higher ...
Cardiology Oct 25, 2012 | not rated yet | 0
Prasugrel, a novel anti-platelet therapy, is used to prevent recurrent cardiovascular events in patients who have had a prior heart attack, suffer severe chest pain and have been treated with coronary artery procedures (revascularization).
Cardiology Oct 24, 2012 | not rated yet | 0
(HealthDay)—A full year of aggressive anti-clotting therapy—which can lead to heavy bleeding—may not be needed after surgery to implant a drug-coated cardiac stent, two new studies suggest.
Cardiology Sep 20, 2012 | not rated yet | 0 |
Clopidogrel is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix. The drug works by irreversibly inhibiting a receptor called P2Y12, an adenosine diphosphate ADP chemoreceptor. Adverse effects include hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP).
For more information about Clopidogrel, read the full article at
This text uses material from Wikipedia and is available under the GNU Free Documentation License.